Hepatitis B virus (HBV) infection is a serious clinical problem.In the Asia-Pacific region, the mother-to-child transmission of HBV from hepatitis B surface antigen (HBsAg)-positive mothers to their i
Conditions
Interventions
control:All infants were vaccinated with HBV vaccine 20mg(within 12 hours of birth, at week 4, and at week 24) and 200 IU of HBIg within 2h of birth and in 15 days or 1 month.
Telbivudine:Cases received telbivudine 600mg per day from week 24-32 of gestation. All infants were vaccinated with HBV vaccine 20mg(within 12 hours of birth, at week 4, and at week 24) and 200 IU of
Sponsors
Institute for Infectious Diseases, Southwest Hospital, Third Military Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: HBeAg+HBV DNA levels>1000000copies/mL mothers received telbivudine 600 mg/day from week 24-32 of gestation.
Exclusion criteria
Exclusion criteria: Pregnant woman whose HBVDNA viral load is low than 1000000 copies/ml.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA and HBV Marker levels in the peripheral blood of mothers during they were received telbivudi;HBV DNA and HBV Marker levels in the peripheral blood of infants before 36 months.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary efficacy assessments included the liver; | — |
Countries
China
Contacts
Public ContactProf Yuming Wang
Outcome results
None listed